Search results
Added:
2 weeks ago
Dr Purvi Parwani (Loma Linda University Health, US) recaps the standout science from Day 2 of ACC 2026, a day defined by a central theme: challenging long-held assumptions in cardiology. Her summary focuses on what these updates mean for day-to-day clinical practice, from prevention strategies to interventional decision-making.Prevention and Risk ReductionVESALIUS-CV: Showed a 25% reduction in…
View more
Added:
1 year ago
ACC 2025 - In this highlights video, Dr Ambarish Pandey (University of Texas Southwestern Medical Center, Texas, US) outlines the key late-breaking trials from the conference that are expected to have an impact on clinical practice.Trials covered in detail include:STRIDESOULFRESH-UPFAIR-HF 2Recorded on-site at ACC in Chicago, 2025.Support: This is an independent interview produced by Radcliffe…
View more
Added:
8 months ago
Learn about the management of HFrEF and HFpEF from Dr Michelle Kittleson (Cedars-Sinai Heart Institute, Los Angeles, US).This two-part video lecture series, part of Women As One's CLIMB® 2025 Skills Training Program, provides a comprehensive overview of key treatments and therapy approaches to cardiomyopathies.In this lecture, Dr Kittleson provides an in-depth review of the management of HFrEF…
View more
Added:
1 year ago
ESC Congress 24 – Join Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (The King Fahd Armed Forces Hospital, SA) for an insightful series of wrap-ups from the ESC Congress 2024 in London.Trials covered in detail include:FINEARTS-HFMRAs in Heart FailureSENIOR RITAEARTH-STEMISCOFFAVATARWatch the Day 1 and Day 2 ESC 24 wrap-ups from Dr Alasnag and Dr Al-Shaibi here.Recorded on-site at the ESC Congress…
View more
Added:
1 year ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,…
View more
Added:
1 year ago
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the findings from a study of four large-scale placebo controlled-trials investigating the timing of cardio-kidney protection with SGLT2 inhibitors.4 trials that sampled distinct patient populations were enrolled in the trial - the CANVAS program, the CREDENCE trial, DAPA-HF and DELIVER. Across each…
View more
Added:
7 months ago
ESC Congress 2025 – The second day of ESC Congress 2025 brought forth significant findings with major implications for cardiovascular care.Interventional specialists Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (King Fahd Armed Forces Hospital, SA) share their expert analysis of the essential insights from the day's hot line trial presentations.Day 2 Highlights:MAPLE-HCMODYSSEY-HCMBETAMI…
View more
Added:
7 months ago
Explore ESC 25 Top Trials with Insights from the Thoraxcenter!Join Prof Nicolas Van MieghemandDr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at ESC 2025.In this comprehensive ESC wrap-up, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices and future research…
View more
Added:
1 year ago
HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two…
View more
Added:
8 months ago
Expert interventionalists, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) discuss the most anticipated hot line studies to be unveiled at ESC Congress 2025. Tune in for their in-depth analysis to get ahead of the curve.ESC Congress 2025 Hot Line Trials Discussed:00:25 DOUBLE-CHOICE03:03 VANTAGE05:03 VICTOR06:28 VICTORIA07:58 DIGIT HF10:19 DAPA ACT HF-TIMI…
View more